Subsequent work has shown that patients with PD-L1-negative tumors showed an aggregate 15% response rate (RR) across many types of cancer.15 PD-L1 expression used as a predictive marker has a poor negative predictive value, therefore selection of patients using only PD-L1 may exclude potentially responding patients. This evidence concerns the gene CD274 and cancer.